Table 2.

Main interview questions

1. What are the sources of information you used before prescribing the drug, or during the course of the treatment?

2. What do you see as the primary objective of the PBS arrangements for access?

3. What do you see as the strengths and weaknesses of the access scheme?

4. Have you been involved in the consultation process in regards to developing restrictions or arrangements to access the TNF inhibitors via the PBS? If yes,

i. Can you briefly describe your role in the consultation process?

ii. Who else took part in the consultation process?

5. Who do you think should take part in the consultation process for formulating the arrangements or restrictions for access?

6. What is the extent of your contact with other rheumatologists, local general practitioners, administrators, consumer organization, the PBAC? And what were the purposes of these contacts?

7. What do you see as the role and responsibility of the prescribers? The PBAC? The industry? Arthritis Foundation?

8. Who, in your view, has responsibility in informing/'educating' the prescribers (and the public) regarding PBS restriction changes, or new complex PBS restrictions?

9. How important an advance do you think the consultation approach and access arrangements represent?

10. If a new and expensive drug comes along that is a significant advance for the treatment of a chronic disease, what differences would you like to see in the process of getting it listed and using it?